CTLA4 and extranodal nasal NK/T cell lymphoma: The combination of pegaspargase and sintilimab is effective and safe for treating advanced-stage NKTCL, with potential benefits in targeting fatty acid metabolism and CTLA-4 to overcome treatment resistance